Thomas M Macdonald - JoVE Visualize

Showing results (101-110 of 143) with videos related to

Pageof 15

Sort By:

Drug Safety|February 19, 2021

Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of PrucaloprideAna Ruigómez, Estel Plana, Alicia Gilsenan, et al.

Paediatric and Perinatal Epidemiology|July 17, 2004

The Walker Project: a longitudinal study of 48,000 children born 1952-1966 (aged 36-50 years in 2002) and their familiesGillian Libby, Anne Smith, Neil F McEwan, et al.

BMJ Open|August 9, 2015

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertensionBryan Williams, Thomas M MacDonald, Mark Caulfield, et al.

BMJ Open|February 11, 2016

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) studyDavid A Rorie, Amy Rogers, Isla S Mackenzie, et al.

BMC Medicine|February 3, 2021

Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attackTian-Tian Ma, Ian C K Wong, Cate Whittlesea, et al.

Journal of Hypertension|April 1, 2011

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronismHari K Parthasarathy, Joel Ménard, William B White, et al.

Heart (British Cardiac Society)|February 21, 2014

High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based studyMaheshwar Pauriah, Douglas H J Elder, Simon Ogston, et al.

BMJ Open|August 9, 2015

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialThomas M MacDonald, Bryan Williams, Mark Caulfield, et al.

Eclinicalmedicine|May 22, 2024

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.

Lancet (London, England)|September 29, 2015

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.

Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:

Pageof 15

Drug Safety|February 19, 2021

Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of PrucaloprideAna Ruigómez, Estel Plana, Alicia Gilsenan, et al.

Paediatric and Perinatal Epidemiology|July 17, 2004

The Walker Project: a longitudinal study of 48,000 children born 1952-1966 (aged 36-50 years in 2002) and their familiesGillian Libby, Anne Smith, Neil F McEwan, et al.

BMJ Open|August 9, 2015

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertensionBryan Williams, Thomas M MacDonald, Mark Caulfield, et al.

BMJ Open|February 11, 2016

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) studyDavid A Rorie, Amy Rogers, Isla S Mackenzie, et al.

BMC Medicine|February 3, 2021

Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attackTian-Tian Ma, Ian C K Wong, Cate Whittlesea, et al.

Journal of Hypertension|April 1, 2011

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronismHari K Parthasarathy, Joel Ménard, William B White, et al.

Heart (British Cardiac Society)|February 21, 2014

High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based studyMaheshwar Pauriah, Douglas H J Elder, Simon Ogston, et al.

BMJ Open|August 9, 2015

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialThomas M MacDonald, Bryan Williams, Mark Caulfield, et al.

Eclinicalmedicine|May 22, 2024

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.

Lancet (London, England)|September 29, 2015

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.

Pageof 15